Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Public ClinicalTrials.gov record NCT05024045. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients With Advanced Hematologic Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to approximately 3 years.
Study identification
- NCT ID
- NCT05024045
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 27 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2021 (Actual)
- Primary completion
- Jun 14, 2023 (Actual)
- Completion
- Mar 2, 2026 (Actual)
- Last update posted
- Oct 6, 2026
2021 – 2026
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The University of Arizona Cancer Center | Tucson | Arizona | 85724 | — |
| City of Hope National Medical Center | Duarte | California | 91010-0269 | — |
| University of California San Francisco, Medical Center at Paranassus | San Francisco | California | 94117 | — |
| Mayo Clinic in Florida | Jacksonville | Florida | 32224 | — |
| Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Indiana Blood & Marrow Transplantation (IBMT) | Indianapolis | Indiana | 46237 | — |
| University of Kansas Medical Center | Westwood | Kansas | 66205 | — |
| Tufts Medical Center | Boston | Massachusetts | 02111 | — |
| Mayo Clinic | Rochester | Minnesota | 55905-0002 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Swedish Medical Center | Seattle | Washington | 98104 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05024045, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 6, 2026 · Synced Nov 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05024045 live on ClinicalTrials.gov.